Pages that link to "Q61868294"
Jump to navigation
Jump to search
The following pages link to BCL-2 antisense therapy in patients with non-Hodgkin lymphoma (Q61868294):
Displaying 50 items.
- Overexpression of nucleolin in chronic lymphocytic leukemia cells induces stabilization of bcl2 mRNA (Q24683723) (← links)
- Targeted therapy against Bcl-2-related proteins in breast cancer cells (Q25257509) (← links)
- Targeting the apoptosis pathway in hematologic malignancies (Q27024422) (← links)
- Antisense treatment directed against mutated Ki-ras in human colorectal adenocarcinoma (Q28345950) (← links)
- Synergistic cytotoxicity of bcl-2 antisense oligodeoxynucleotides and etoposide, doxorubicin and cisplatin on small-cell lung cancer cell lines (Q28469349) (← links)
- Nucleocytoplasmic shuttling: a novel in vivo property of antisense phosphorothioate oligodeoxynucleotides. (Q30453773) (← links)
- Quantitative assessment of chimeraplast stability in biological fluids by polyacrylamide gel electrophoresis and laser-assisted fluorescence analysis (Q30838222) (← links)
- Recent advances in the development of anticancer agents targeting cell death inhibitors in the Bcl-2 protein family (Q30971455) (← links)
- A small inhibitor of the interaction between Bax and Bcl-X(L) can synergize with methylprednisolone to induce apoptosis in Bcl-X(L)-overexpressing breast-cancer cells (Q31150898) (← links)
- Antisense to the Epstein-Barr virus (EBV)-encoded latent membrane protein 1 (LMP-1) sensitizes EBV-immortalized B cells to transforming growth factor-beta and chemotherapeutic agents (Q31811732) (← links)
- Oligonucleotide‐Based Knockdown Technologies: Antisense Versus RNA Interference (Q33193599) (← links)
- Antisense--time to shoot the messenger (Q33693109) (← links)
- Preclinical and clinical pharmacology of antisense oligonucleotides (Q33770561) (← links)
- Gene therapy of pediatric leukemia. (Q33854489) (← links)
- Antisense therapeutics in chronic myeloid leukaemia: the promise, the progress and the problems (Q33864554) (← links)
- Reversible tumorigenesis by MYC in hematopoietic lineages (Q33874286) (← links)
- Antisense oligonucleotides as a tool for gene functionalization and target validation (Q33916097) (← links)
- Oligonucleotide therapeutics for hematologic disorders (Q33916119) (← links)
- Human Bcl-2 antisense therapy for lymphomas (Q33916124) (← links)
- Follicular lymphomas--a review of treatment modalities. (Q33947861) (← links)
- Synthetic oligonucleotides as therapeutics: the coming of age. (Q33955684) (← links)
- Structural chemistry and therapeutic intervention of protein-protein interactions in immune response, human immunodeficiency virus entry, and apoptosis (Q33959645) (← links)
- Antisense oligonucleotides: an evolving technology for the modulation of gene expression in human disease (Q33970374) (← links)
- Mucosal adjuvanticity of immunostimulatory DNA sequences (Q34005448) (← links)
- Potential applications of gene therapy in the patient with cancer (Q34030512) (← links)
- The apoptotic pathway: a target for therapy in chronic lymphocytic leukemia (Q34057963) (← links)
- Antisense cancer therapy: the state of the science (Q34107762) (← links)
- Apoptosis and cancer: strategies for integrating programmed cell death (Q34124148) (← links)
- Potential roles of antisense oligonucleotides in cancer therapy. The example of Bcl-2 antisense oligonucleotides (Q34160291) (← links)
- Role of Bcl-2 and its post-transcriptional modification in response to antitumor therapy. (Q34166893) (← links)
- Salvage therapy for refractory or relapsed acute lymphocytic leukemia (Q34186583) (← links)
- Bcl-2 family proteins as targets for anticancer drug design (Q34293584) (← links)
- Telomere maintenance mechanisms as a target for drug development (Q34293590) (← links)
- Potential roles of antisense technology in cancer chemotherapy (Q34293601) (← links)
- Oligonucleotide treatment of ras-induced tumors in nude mice (Q34300042) (← links)
- Current status of ribozymes as gene therapy agents for cancer (Q34311089) (← links)
- Targeting telomeres and telomerase (Q34330916) (← links)
- Targeting apoptosis in prostate cancer (Q34348279) (← links)
- Antisense oligonucleotide against hTERT (Cantide) inhibits tumor growth in an orthotopic primary hepatic lymphoma mouse model (Q34358498) (← links)
- Site-specific strand breaks in RNA produced by (125)I radiodecay (Q34369245) (← links)
- Apoptosis, Part I: Biochemical assessment (Q34404626) (← links)
- Targeting anti-apoptotic genes upregulated by androgen withdrawal using antisense oligonucleotides to enhance androgen- and chemo-sensitivity in prostate cancer (Q34722249) (← links)
- Nucleic-acid therapeutics: basic principles and recent applications (Q34743204) (← links)
- Delivery of antisense oligodeoxyribonucleotide lipopolyplex nanoparticles assembled by microfluidic hydrodynamic focusing (Q34906198) (← links)
- The chemical biology of apoptosis. Exploring protein-protein interactions and the life and death of cells with small molecules (Q34980881) (← links)
- Antisense therapy for cancer--the time of truth (Q34992794) (← links)
- Regulators of apoptosis as anticancer targets (Q35038784) (← links)
- Molecular targets in therapy for human soft-tissue and bone sarcomas (Q35142828) (← links)
- Antisense therapeutics: from theory to clinical practice (Q35153742) (← links)
- Synthesis and application of functional peptides as cell nucleus‐directed molecules in the treatment of malignant diseases (Q35549395) (← links)